 |
13 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- | AMG 811 / Amgen
Biomarker, Journal: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Subjects with Discoid Lupus Erythematosus. (Pubmed Central) - Aug 16, 2017
AMG 811 treatment led to changes in IFNγ-associated biomarkers and was well tolerated, but no significant clinical benefit was observed in patients with DLE.
- | AMG 811 / Amgen
New P1 trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 14, 2014
P1, N=26, Completed, Sponsor: Amgen
- AMG 811 / Amgen
Enrollment change, Trial termination, Trial primary completion date: Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus (clinicaltrials.gov) - Sep 16, 2014
P1, N=16, Terminated, Sponsor: Amgen
AMG 811 treatment led to changes in IFNγ-associated biomarkers and was well tolerated, but no significant clinical benefit was observed in patients with DLE. N=20 --> 16 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Sep 2012; The 16 subjects enrolled in the study should enable Amgen to adequately assess safety and tolerabili
- ||| AMG 811 / Amgen
Trial completion: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - Sep 15, 2014
P1, N=56, Completed, Sponsor: Amgen
N=20 --> 16 | Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Sep 2012; The 16 subjects enrolled in the study should enable Amgen to adequately assess safety and tolerabili Active, not recruiting --> Completed
- || AMG 811 / Amgen
Trial primary completion date: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - May 14, 2014
P1, N=56, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Jun 2014
- | AMG 811 / Amgen
Trial completion date: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - May 14, 2014
P1, N=56, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2014 --> Jun 2014 Trial completion date: Jul 2014 --> Aug 2014
- || AMG 811 / Amgen
Enrollment closed: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - Jan 12, 2014
P1, N=56, Active, not recruiting, Sponsor: Amgen
Trial completion date: Jul 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- AMG 811 / Amgen
Trial completion: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis (clinicaltrials.gov) - Mar 24, 2013
P1, N=9, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Completed
- AMG 811 / Amgen
New P1 trial: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis (clinicaltrials.gov) - Jan 16, 2012
P1, N=9, Completed, Sponsor: Amgen